-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Neutral on Calumet, Raises Price Target to $47

Benzinga·08/25/2026 16:20:55
Listen to the news
UBS analyst Manav Gupta maintains Calumet (NASDAQ:CLMT) with a Neutral and raises the price target from $26 to $47.